Wedbush Weighs in on DexCom, Inc.’s FY2017 Earnings (DXCM)
DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Wedbush increased their FY2017 EPS estimates for shares of DexCom in a report released on Thursday. Wedbush analyst Levy. T now forecasts that the medical device company will post earnings of ($0.63) per share for the year, up from their previous estimate of ($0.71). Wedbush currently has a “Buy” rating and a $76.00 target price on the stock. Wedbush also issued estimates for DexCom’s Q4 2017 earnings at $0.03 EPS, FY2018 earnings at ($0.52) EPS and FY2019 earnings at $0.02 EPS.
Other equities research analysts have also issued reports about the company. Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 price target on shares of DexCom in a research report on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $92.00 price target on DexCom and gave the company a “buy” rating in a research report on Wednesday, August 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $62.00 price target (down from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Northland Securities lowered DexCom from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $85.00 to $60.00 in a research report on Thursday, September 28th. Finally, BidaskClub lowered DexCom from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $70.69.
WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/08/wedbush-weighs-in-on-dexcom-inc-s-fy2017-earnings-dxcm.html.
Shares of DexCom (NASDAQ:DXCM) opened at $50.11 on Monday. DexCom has a 12-month low of $42.62 and a 12-month high of $88.80. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.
A number of hedge funds and other institutional investors have recently modified their holdings of DXCM. Advisor Group Inc. boosted its stake in DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares during the period. IFP Advisors Inc boosted its stake in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after purchasing an additional 568 shares during the period. Toronto Dominion Bank boosted its stake in DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after purchasing an additional 2,608 shares during the period. Independent Portfolio Consultants Inc. boosted its stake in DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after purchasing an additional 9 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after purchasing an additional 250 shares during the period.
In other news, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the completion of the transaction, the executive vice president now owns 65,049 shares in the company, valued at approximately $2,915,496.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The disclosure for this sale can be found here. Insiders have sold a total of 23,208 shares of company stock valued at $1,597,567 in the last quarter. 1.70% of the stock is owned by corporate insiders.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.